NCT01950364 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma (NCT01950364)

Trial Description
This is an open-label trial to estimate the concentrations of MMAE in relapsed/refractory Hodgkin Lymphoma (HL) or relapsed/refractory Systemic Anaplastic Large Cell Lymphoma (sALCL) patients treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

This trial is sponsored by Millennium Pharmaceuticals. [1]

Study Data

Study Schematic

Screen Shot 2016-07-18 at 3.15.44 PM

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.